- Home
- FISI vs CTMX Comparison
FISI vs CTMX Comparison
Compare FISI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- CTMX
- Stock Information
- Founded
- FISI 1817
- CTMX 2008
- Country
- FISI United States
- CTMX United States
- Employees
- FISI N/A
- CTMX N/A
- Industry
- FISI Major Banks
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- FISI Finance
- CTMX Health Care
- Exchange
- FISI Nasdaq
- CTMX Nasdaq
- Market Cap
- FISI 522.5M
- CTMX 444.3M
- IPO Year
- FISI 1999
- CTMX 2015
- Fundamental
- Price
- FISI $24.60
- CTMX $2.33
- Analyst Decision
- FISI Buy
- CTMX Strong Buy
- Analyst Count
- FISI 3
- CTMX 2
- Target Price
- FISI $33.00
- CTMX $5.00
- AVG Volume (30 Days)
- FISI 108.0K
- CTMX 3.3M
- Earning Date
- FISI 07-24-2025
- CTMX 08-07-2025
- Dividend Yield
- FISI 5.03%
- CTMX N/A
- EPS Growth
- FISI N/A
- CTMX 128.27
- EPS
- FISI N/A
- CTMX 0.49
- Revenue
- FISI $108,628,000.00
- CTMX $147,557,000.00
- Revenue This Year
- FISI $101.16
- CTMX N/A
- Revenue Next Year
- FISI $6.68
- CTMX N/A
- P/E Ratio
- FISI N/A
- CTMX $4.78
- Revenue Growth
- FISI N/A
- CTMX 23.81
- 52 Week Low
- FISI $17.27
- CTMX $0.40
- 52 Week High
- FISI $29.79
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- FISI 39.93
- CTMX 49.57
- Support Level
- FISI $24.41
- CTMX $2.08
- Resistance Level
- FISI $26.60
- CTMX $3.10
- Average True Range (ATR)
- FISI 0.46
- CTMX 0.26
- MACD
- FISI -0.19
- CTMX -0.11
- Stochastic Oscillator
- FISI 8.68
- CTMX 15.20
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.